Loomis, Sayles & Company
FPRX

Loomis, Sayles & Company’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Loomis, Sayles & Company’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-130
Closed -$7K – 1064
2016
Q4 		$7K Hold
130
– – ﹤0.01% 879
2016
Q3 		$7K Hold
130
– – ﹤0.01% 837
2016
Q2 		$5K Buy
+130
New +$5.66K ﹤0.01% 861

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Loomis, Sayles & Company's FPRX Position: Q1 2017 in Review

Loomis, Sayles & Company sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 130 shares — an estimated $7K sold.

Loomis, Sayles & Company first reported a position in FPRX in Q2 2016 and held it in 3 quarters. The position peaked at $7K in Q4 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Loomis, Sayles & Company reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 130 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $7K.
  • Loomis, Sayles & Company first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
  • Loomis, Sayles & Company's Five Prime Therapeutics, Inc. position peaked at $7K in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Loomis, Sayles & Company's 13F filing for Q1 2017, filed 12 May 2017.